The Lynx Group

Value Propositions

Quest Diagnostics, the leading provider of diagnostic testing, has introduced a new laboratory test that identifies molecular changes to cervical cells that may signal increased risk for cervical cancer.
Read Article


Several researchers at the University of Rochester Medical Center have been studying the effects of exercise on patients with cancer for some time now.
Read Article

Greenville Hospital System (GHS) has launched the Center for Integrative Oncology and Survivorship, which offers emotional services for cancer survivors developed by Cancer Support Community (CSC), an international provider of cancer-related social and emotional services.
Read Article

Texas Children’s Cancer Center has opened the first center dedicated entirely to the research, care, and treatment of children with lymphoma. The Fayez Sarofim Lymphoma Center at Texas Children’s Cancer Center was made possible by a gift of $10 million to Texas Children’s Hospital.
Read Article

A team of researchers from the University of Colorado led by Tyler Robin, PhD, Department of OB/GYN, Denver Anschutz Medical Campus, has discovered a new biomarker in Ewing’s sarcoma that explains the lack of disease response to current chemotherapy in some patients with this cancer, who until now have had a very poor prognosis.
Read Article

>According to Genome Health Solutions cofounder Mark S. Boguski, MD, PhD, FCAP, Harvard Medical School’s Center for Biomedical Informatics and Beth Israel Deaconess Medical Center, at this point in time, the promise of genomics lies “not so much in therapeutics or disease prevention, but in precision diagnostics that will really enable personalized medicine.
Read Article

Two of the largest diagnostic imaging centers in the country—Insight Imaging in California and Centers for Diagnostic Imaging (CDI) in Minneapolis—have announced that they are merging forces.
Read Article

At the 2012 annual meeting of the Society of Nuclear Medicine, researchers presented new results for the radioisotope therapy radium-223 chloride, suggesting that these results represent a new treatment protocol for patients with advanced prostate cancer that has spread to the bone.
Read Article

A study funded by the National Cancer Institute, the National Institutes of Health, a Theodore N. Law Endowment for Scientific Achievement, and a Dodie P. Hawn Fellowship in Cancer Genetics Research surprisingly showed that the presence of normal p53, a tumor suppressor gene and not the mutated gene, was making chemotherapy with doxorubicin less effective in breast cancer; it is the mutated gene that actually enhances the benefit of the drug and not the reverse.
Read Article

Page 7 of 11

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: